Subscribe to our Newsletters !!
Fermentation is a natural method which is applied
In the world of Biochemistry, Microbiology and Pha
The human metapneumovirus, more simply referred to
Indegene, a digital-first life sciences commercial
Alembic Pharmaceuticals Limited (Alembic) announce
'Simplicity' seems to be the perfect word to descr
Dear Readers, Welcome to the latest issue of The Magazine
New Delhi, Dec 3 (PTI) Drug firm Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator for Metolazone tablets, indicated for the treatment of salt and water retention caused by heart failure or kidney disease. The approved product is therapeutically equivalent to the reference listed drug product Zaroxolyn Tablets 2.5 mg, 5 mg and 10 mg of Lannett Company, Inc..
In a regulatory filing, Alembic Pharmaceuticals stated”it has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg”.
Metolazone tablets are indicated for the treatment of salt and water retention such as edema accompanying congestive heart failure, edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.
Metolazone tablets are also indicated for the treatment of hypertension, either alone or in combination with other antihypertensive drugs of another class.
Quoting IQVIA data, Alembic Pharma stated Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg have an estimated market size of USD 33 million to 12 months ending September 2020.
PTI SVK ANS ANS
